These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25803816)

  • 41. Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status.
    Pietrantonio F; Maggi C; Di Bartolomeo M; Facciorusso MG; Perrone F; Testi A; Iacovelli R; Miceli R; Bossi I; Leone G; Milione M; Pelosi G; de Braud F
    PLoS One; 2014; 9(4):e92147. PubMed ID: 24691006
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
    Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluating the effectiveness of RNA in-situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement.
    Nakajima N; Yoshizawa A; Kondo K; Rokutan-Kurata M; Hirata M; Furuhata A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Fujimoto M; Date H; Haga H
    Histopathology; 2017 Jul; 71(1):143-149. PubMed ID: 28231386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A new look at the ALK gene in cancer: copy number gain and amplification.
    Zito Marino F; Rocco G; Morabito A; Mignogna C; Intartaglia M; Liguori G; Botti G; Franco R
    Expert Rev Anticancer Ther; 2016 May; 16(5):493-502. PubMed ID: 26943457
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of germline variants in inflammatory breast cancer.
    Rana HQ; Sacca R; Drogan C; Gutierrez S; Schlosnagle E; Regan MM; Speare V; LaDuca H; Dolinsky J; Garber JE; Overmoyer BA
    Cancer; 2019 Jul; 125(13):2194-2202. PubMed ID: 30933323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening for ALK abnormalities in central nervous system metastases of non-small-cell lung cancer.
    Nicoś M; Jarosz B; Krawczyk P; Wojas-Krawczyk K; Kucharczyk T; Sawicki M; Pankowski J; Trojanowski T; Milanowski J
    Brain Pathol; 2018 Jan; 28(1):77-86. PubMed ID: 27879019
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
    Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
    J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma.
    Yang P; Kulig K; Boland JM; Erickson-Johnson MR; Oliveira AM; Wampfler J; Jatoi A; Deschamps C; Marks R; Fortner C; Stoddard S; Nichols F; Molina J; Aubry MC; Tang H; Yi ES
    J Thorac Oncol; 2012 Jan; 7(1):90-7. PubMed ID: 22134072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anaplastic Lymphoma Kinase Immunocytochemistry on Cell-Transferred Cytologic Smears of Lung Adenocarcinoma.
    Zhang C; Randolph ML; Jones KJ; Cramer HM; Cheng L; Wu HH
    Acta Cytol; 2015; 59(2):213-8. PubMed ID: 25967762
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inflammatory breast cancer: a single centre analysis.
    Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK; Sharma DN
    Asian Pac J Cancer Prev; 2014; 15(7):3207-10. PubMed ID: 24815472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinicopathological Features and Therapeutic Responses of Chinese Patients with Advanced Lung Adenocarcinoma Harboring an Anaplastic Lymphoma Kinase Rearrangement.
    Lin D; Zeng D; Chen C; Wu X; Wang M; Chen J; Lin H; Qiu X
    Oncol Res Treat; 2017; 40(1-2):27-33. PubMed ID: 28118634
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
    Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
    J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
    Camidge DR; Theodoro M; Maxson DA; Skokan M; O'Brien T; Lu X; Doebele RC; Barón AE; Varella-Garcia M
    Cancer; 2012 Sep; 118(18):4486-94. PubMed ID: 22282074
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.
    Jang JS; Wang X; Vedell PT; Wen J; Zhang J; Ellison DW; Evans JM; Johnson SH; Yang P; Sukov WR; Oliveira AM; Vasmatzis G; Sun Z; Jen J; Yi ES
    J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.
    Diessner J; Van Ewijk R; Weiss CR; Janni W; Wischnewsky MB; Kreienberg R; Hancke K; Blettner M; Wöckel A; Schwentner L
    Arch Gynecol Obstet; 2015 Sep; 292(3):655-64. PubMed ID: 25814296
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MARCKS protein overexpression in inflammatory breast cancer.
    Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
    Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
    Pelosi G; Gasparini P; Cavazza A; Rossi G; Graziano P; Barbareschi M; Perrone F; Barberis M; Takagi M; Kunimura T; Yamada T; Nakatani Y; Pastorino U; Scanagatta P; Sozzi G; Garassino M; De Braud F; Papotti M
    Lung Cancer; 2012 Sep; 77(3):507-14. PubMed ID: 22705117
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
    Camidge DR; Skokan M; Kiatsimkul P; Helfrich B; Lu X; Barón AE; Schulte N; Maxson D; Aisner DL; Franklin WA; Doebele RC; Varella-Garcia M
    Cancer; 2013 Nov; 119(22):3968-75. PubMed ID: 24022839
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population.
    Ying J; Lin C; Wu J; Guo L; Qiu T; Ling Y; Shan L; Zhou H; Zhao D; Wang J; Liang J; Zhao J; Jiao Y; Lu N; Zhao H
    PLoS One; 2015; 10(12):e0144731. PubMed ID: 26678488
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.
    Li J; Gonzalez-Angulo AM; Allen PK; Yu TK; Woodward WA; Ueno NT; Lucci A; Krishnamurthy S; Gong Y; Bondy ML; Yang W; Willey JS; Cristofanilli M; Valero V; Buchholz TA
    Oncologist; 2011; 16(12):1675-83. PubMed ID: 22147002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.